Adenosine Receptors in Neurodegenerative Diseases
- 1st Edition - March 30, 2017
- Editors: David Blum, Luisa V. Lopes
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 0 3 7 2 4 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 3 7 4 5 - 4
Adenosine Receptors in Neurodegenerative Diseases covers the role of adenosine receptors in brain function, also focusing on related methodologies and perspectives in therapeut… Read more
Purchase options
Adenosine Receptors in Neurodegenerative Diseases covers the role of adenosine receptors in brain function, also focusing on related methodologies and perspectives in therapeutics. The book provides an up-to-date overview by the best specialists in the field, helping readers consider the importance of adenosine and expand the global impact and visibility of adenosine research in the CNS field.
Chapters include adenosine biology and signaling, gene regulation, control of motor function, and novel adenosine-based therapies in the CNS. It is an ideal resource for researchers, advanced graduate students, clinicians, and industry scientists working in the fields of clinical neuroscience and molecular and cellular neuroscience.
- Comprehensive reference that details adenosine receptors in neurodegenerative disorders, with details on brain function and possible therapeutics
- Gives insights on how these receptors modulate the neurodegenerative outcomes in different disorders
- Edited by two of the leading researchers in the field regarding adenosine role in the brain in aging and neurodegenerative conditions
Advanced graduate students, researchers, clinicians, and industry scientists in the fields of neurodegeneration, neuroscience, neurology, and neuropharmacology
Section I: Physiology
Chapter 1. Adenosine Receptor Biology in the Central Nervous System
- Abstract
- Sources of Adenosine in the CNS
- Receptor Subtypes and Their CNS Distribution
- Crosstalk With Other Receptors
- Adenosine and CNS Diseases
- Recent Clinical Trials
- References
Chapter 2. Adenosine Signaling Throughout Development
- Abstract
- Introduction
- Effects of Adenosine Signaling and Its Dysfunction in CNS
- Effects of Adenosine in Oligodendrocytes Development
- Effects of Adenosine on Cardiovascular System During Embryogenesis
- Postnatal Effects of Adenosine on Cardiovascular System
- Postnatal Effect of Adenosine on Respiratory System
- Use of Methylxanthines in Premature Babies
- Postnatal Effects of Adenosine on the Genitourinary System
- Postnatal Effect of Adenosine on the Enteric System
- Postnatal Effect of Adenosine on Other Systems
- Conclusion
- References
Chapter 3. Influence of Adenosine on Synaptic Excitability
- Abstract
- Introduction
- Molecular & Physiological Mechanisms
- Implications for Epilepsy
- Conclusions and Outlook
- Acknowledgments
- References
Chapter 4. Regulation of Synaptic Transmission by Adenosine at the Neuromuscular Junction
- Abstract
- Introduction
- Neuromuscular Junction
- Adenosine as a Neuromodulator at the Neuromuscular Junction
- Conclusions
- References
Chapter 5. Gene Regulation of Adenosine A2A Receptors in the Central Nervous System
- Abstract
- General Introduction
- A2AR Promoter and Gene Structure
- Epigenetics of ADORA2A
- Use of DNA Methylating Agents as a Therapeutic Tool
- The Dual Codon Properties of the A2AR Gene
- Concluding Remarks
- Acknowledgments
- References
Section II: Pathology
Chapter 6. Sleep, Adenosine, and Neurodegeneration
- Abstract
- Sleep Phenomenology and Adenosine
- Sleep and Adenosine Changes Across Normal Ageing
- Sleep Changes in Alzheimer’s Disease
- Mechanisms of Alzheimer’s Disease Influence on Sleep
- Changes in ADORA1 and ADORA2 Expression
- Association of Alzheimer’s Disease Biomarkers and Sleep
- Role of Sleep Loss in Alzheimer’s Disease
- Sleep Changes in Parkinson’s Disease
- Parkinson’s Disease Role in Sleep Pathology
- Role of Sleep Loss in Parkinson’s Disease Pathology
- Treatment Related Issues
- Summary
- References
Chapter 7. Neuronal vs Glial Cell Contribution to Adenosine A2A Receptor-Induced Neurodegeneration
- Abstract
- Neurodegeneration and Neurodegenerative Diseases
- Role of A2A Receptors in Neurodegeneration
- Conclusions
- References
Chapter 8. Adenosine and Oxygen/Glucose Deprivation in the Brain
- Abstract
- Introduction
- Adenosine is Released by Ischemia and Stimulate All P1 Receptor Subtypes
- Role of Adenosine Receptors in Ischemia
- Conclusions
- Acknowledgments
- References
Chapter 9. Adenosine Receptors and Memory Disorders
- Abstract
- Alzheimer’s Disease
- Caffeine May Protect Against Cognitive Decline and AD
- Caffeine, Adenosine Receptor and AD Lesions
- Conclusion
- Acknowledgments
- References
Chapter 10. Control of Motor Function by Adenosine A2A Receptors in Parkinson’s and Huntington’s Disease
- Abstract
- Introduction
- Basal Ganglia Circuitry
- Adenosine A2A Receptor Antagonists
- Parkinson’s Disease
- Effect of A2A Receptor Antagonists on Motor and Sensorimotor Deficits
- Modulation of Adenosine A2A Receptors and Interaction With the Other Neurotransmitter Systems
- Adenosine A2A Receptors and Huntington’s Disease
- Conclusions
- References
Chapter 11. Adenosine Receptors Oligomers in Parkinson’s Disease
- Abstract
- Introduction
- Adenosine Receptors in the Brain
- Adenosine Receptor-Containing Oligomers
- Parkinson’s Disease and Adenosine Receptor Oligomers: Impact on Pharmacotherapy
- Concluding Remarks
- Acknowledgments
- References
Chapter 12. Adenosine Control of Striatal Function—Implications for the Treatment of Apathy in Basal Ganglia Disorders
- Abstract
- Introduction
- Dopamine Control of Striatal Function
- Differential Dopamine Control of the Direct and Indirect Striatal Efferent Pathways, the “Go” and “NoGo” Pathways
- Differential Adenosine Control of the “Go” and “NoGo” Pathways. The Adenosine–Dopamine Receptor Heteromers
- Adenosine Control of the Striatal Glutamate Terminal. The A1R–A2AR Heteromer
- Dopamine and Striatal Dysfunction. Apathy Versus Akinesia
- Targeting Adenosine Receptor Heteromers for the Treatment of Apathy
- Acknowledgments
- References
- Edition: 1
- Published: March 30, 2017
- Language: English
DB
David Blum
Dr. David Blum is Research Director at Inserm in the “Alzheimer & Tauopathies” laboratory, a founder unit of the Jean-Pierre Aubert Research Centre (UMR-S 1172; Lille, France). His group is particularly focused on how environmental factors affect brain disorders with a particular interest towards caffeine. His current topic in this field relates to the impact of adenosine receptor modulation in neurological and neurodegenerative disorders as well as to the better understanding of molecular effects of caffeine into the brain. David has also a strong interest to translate his findings towards clinical studies, epidemiological and genetics. David graduated at Strasbourg University, France; obtained his PhD in Neurosciences at Grenoble University, France in 1999; and developed post-doctoral research experience at ULB, Brussels, Belgium. He has been recruited as senior researcher at Inserm in 2006. His main contributions includes the description of the complex role of adenosine receptors in Huntington’s disease and the first demonstration of regulatory role of A2A receptor contribution in Tauopathies (with Dr. Lopes). David authors more that 90 papers with more that 2500 citations, including top Neuroscience Journals as Lancet Neurology, Molecular Psychiatry, Journal of Neuroscience, Neurobiology of Aging or Human Molecular Genetics. David serves in several editorial boards as associate editors and as expert for most Neuroscience journals and fundings agencies in his field.
Affiliations and expertise
Inserm UMR-1172 and Université de Lille, Lille, FranceLL
Luisa V. Lopes
Luísa V. Lopes is a Group leader@iMM Lisboa, Portugal. Her current work focuses on understanding the mechanisms inducing the "early-aging" of the cognitive function. The team has extensively provided evidence for an important contribution of adenosine receptors in pathophysiological context, and their impact in noxious brain conditions such as stress, aging and neurodegeneration, being awarded by FEBS, FENS and EMBO. Luisa graduated in Lisbon in 1998 in Biochemistry and then pursued a PhD in Neurosciences being trained in the University of Cambridge, UK and at the Karolisnka Institute, Sweden. She acquired postdoctoral experience in a company setting (Nestlé Research Center; Switzerland) studying brain-gut interactions with particular focus on early-life stress. Luisa established her own research group in 2013 as recipient of an Investigator FCT position. Her contribution includes providing the crucial first evidence of a possible glucocorticoid-adenosine link in Alzheimer’s disease (with D. Blum) following previous groundwork suggesting circadian disorders as a trigger for accelerated cognitive loss. She has authored more than 40 papers in international peer-reviewed journals with over 1000 citations. These include top journals in the field of neuroscience, such as Molecular Psychiatry, Neurobiology of Ageing, Journal of Neuroscience, as a senior author; including an award publication in TINS. Luisa has also served as a Board Member of Portuguese Society for Neuroscience and got an award from DANA Alliance for her work in raising public awareness for brain research.
Affiliations and expertise
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, PortugalRead Adenosine Receptors in Neurodegenerative Diseases on ScienceDirect